US launches Section 301 probe into Germany's pharma pricing policies

The United States has opened a trade investigation into Germany's pharmaceutical pricing policies, raising the prospect of new tariffs on a major European economy. The move was announced on Thursday and is being carried out under Section 301 of the Trade Act of 1974. It focuses on whether Germany's pricing practices for innovative medicines unfairly burden US commerce.

Sponsored

According to the US Trade Representative's office, the probe will examine whether Germany's approach amounts to persistent underpayment for innovative pharmaceutical products that is unreasonable or discriminatory. The notice said evidence indicates Germany uses unfair pricing policies and practices in relation to innovative medicines. It also said reduced revenue linked to those practices appears to contribute to lower investment in research and development.

US Trade Representative Jamieson Greer said President Donald Trump had made clear that American patients should not be shouldering a disproportionate share of global pharmaceutical research and development. The office also said it was concerned about Germany's plans to fast-track legislation that would further reduce spending on innovative pharmaceuticals. The investigation will next take comments and hold a hearing in September.

The case matters because Section 301 investigations can be used to justify trade remedies, including tariffs, if the US concludes that a trading partner's policies are unfair. Germany is one of the world's largest economies and a major market for pharmaceutical products, so any escalation could affect both trade relations and the wider medicines sector. The probe also comes as Washington has been using similar authorities more broadly against trading partners over issues including forced labour and industrial overcapacity.

Sponsored

The notice said the inquiry will look at the means Germany uses to implement its pricing policies and practices. It also argued that the United States pays a disproportionate share of global research and development costs for innovative pharmaceuticals. That framing suggests the dispute is not only about prices, but also about how the costs of drug innovation are shared internationally.

What happens next will depend on the evidence gathered, the comments submitted, and the September hearing. It is not yet clear whether the investigation will lead to tariffs or other trade measures. The key issue to watch is whether the US concludes that Germany's pricing system is discriminatory or burdens US commerce, and whether Berlin responds before the process advances further.

#UnitedStates #Germany #pharmaceuticalpricing #Section301 #tariffs